Référentiel des médicaments
Dapagliflozin-saxagliptin
Dapagliflozin-saxagliptin is a medicine in the class gastrointestinal tract. It is used for diabetes mellitus.
- Classe médicamenteuse: Gastrointestinal Tract
- Indications: diabetes mellitus
Dernière mise à jour
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Gastrointestinal Tract
- Code ATC
- A10BD21
- Formes courantes
- comprimé
- Dosages courants
- 5 mg
- Noms commerciaux
- 3
- Pays et marchés
- 3
Indications
Mécanisme d'action
Dapagliflozin: Selective sodium-glucose transporter-2 (SGLT2) inhibitor; SGLT-2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion
Posologie adulte habituelle (résumé de la notice)
Type 2 Diabetes Mellitus: 1 tablet (ie, 10mg/5mg) PO qDay in AM with or without food
Grossesse et allaitement
- Grossesse
- Unsafe Dapagliflozin: kidney changes in rat offspring; not recommended in the 2nd and 3rd trimesters. Saxagliptin: limited data, no harm in animals. Stop the combination when pregnancy is detected; insulin is preferred.
- Allaitement
- Unsafe No human milk data for either component; both pass into rat milk. Because of possible serious infant reactions (dapagliflozin and kidney maturation), the US label advises not to breastfeed.
Effets indésirables signalés
- Diarrhea
- Back Pain
- Upper respiratory tract infection (URI)
- Urinary tract infections
- Dyslipidemia
- Headaches
Contre-indications
- History of hypersensitivity to dapagliflozin or saxagliptin, including anaphylaxis, angioedema, or exfoliative skin conditions
- Moderate-to-severe renal impairment (eGFR <45 mL/min/1.73 m²), end-stage renal disease, or patients on dialysis
Précautions particulières
- Acute pancreatitis reported; after initiating drug, monitor for signs and symptoms of pancreatitis; if suspected, promptly discontinue dapagliflozin/saxagliptin and initiate appropriate management
- May increase risk for developing heart failure (HF) or exacerbation of existing HR; observe patients for signs and symptoms of HF
- Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization reported in patients receiving SGLT2 inhibitors, including dapagliflozin; treatment with SGLT2 inhibitors increases risk for urinary tract infections; evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Dapagliflozin-saxagliptin : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Dapagliflozin-saxagliptin used for?
Dapagliflozin-saxagliptin is a medicine in the class gastrointestinal tract. It is used for Diabetes mellitus.
What side effects have been reported with Dapagliflozin-saxagliptin?
Diarrhea, Back Pain, Upper respiratory tract infection (URI), Urinary tract infections, Dyslipidemia, Headaches.
Can Dapagliflozin-saxagliptin be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Dapagliflozin: kidney changes in rat offspring; not recommended in the 2nd and 3rd trimesters. Saxagliptin: limited data, no harm in animals. Stop the combination when pregnancy is detected; insulin is preferred. Breastfeeding: Unsafe. No human milk data for either component; both pass into rat milk. Because of possible serious infant reactions (dapagliflozin and kidney maturation), the US label advises not to breastfeed.
What does Dapagliflozin-saxagliptin interact with?
MediHelp does not list a checked interaction for Dapagliflozin-saxagliptin yet. Always tell your pharmacist about every medicine you take.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
